Gareth Hughes

10PUBLICATIONS
73CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar

|Aug 03, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.

Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo

|Apr 07, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.

Alexey Revenko, Larissa S Carnevalli, Charles Sinclair

|Jan 26, 2022
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.

Zena Wilson, Rajesh Odedra, Yann Wallez

|Mar 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.

Larissa S Carnevalli, Molly A Taylor, Matthew King

|Sep 18, 2020
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.

Theresa A Proia, Maneesh Singh, Richard Woessner

Pageof 2

Frequent Collaborators

5 joint publications

Larissa S Carnevalli

4 joint publications

Mark J O'Connor

3 joint publications

Simon T Barry

2 joint publications

Molly A Taylor